Media stories about Centene (NYSE:CNC) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Centene earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.3619016738738 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Shares of Centene (CNC) traded down $0.09 during midday trading on Tuesday, hitting $103.00. 1,430,000 shares of the stock traded hands, compared to its average volume of 1,410,000. Centene has a 1-year low of $65.03 and a 1-year high of $112.42. The firm has a market capitalization of $17,770.00, a price-to-earnings ratio of 21.96, a price-to-earnings-growth ratio of 0.96 and a beta of 0.71. The company has a current ratio of 0.93, a quick ratio of 0.99 and a debt-to-equity ratio of 0.68.

Centene (NYSE:CNC) last announced its earnings results on Tuesday, February 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.03. Centene had a net margin of 1.71% and a return on equity of 13.68%. The business had revenue of $12.81 billion for the quarter, compared to analyst estimates of $12.25 billion. During the same quarter last year, the business earned $1.19 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. equities analysts expect that Centene will post 7.23 EPS for the current fiscal year.

Several analysts recently commented on CNC shares. Credit Suisse Group started coverage on shares of Centene in a research report on Thursday, November 2nd. They set a “neutral” rating and a $102.00 price target on the stock. Oppenheimer raised their price target on shares of Centene from $111.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, December 20th. BMO Capital Markets started coverage on shares of Centene in a research report on Tuesday, October 17th. They set an “outperform” rating and a $120.00 price target on the stock. Cantor Fitzgerald restated a “buy” rating and set a $107.00 price target on shares of Centene in a research report on Tuesday, October 24th. Finally, ValuEngine upgraded shares of Centene from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Three research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $110.28.

In other news, EVP Keith H. Williamson sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $100.11, for a total value of $500,550.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert K. Ditmore sold 8,750 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $104.13, for a total transaction of $911,137.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,500 shares of company stock worth $3,311,613. Insiders own 3.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at

Centene Company Profile

Centene Corporation is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. The Company’s Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children’s Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace.

Insider Buying and Selling by Quarter for Centene (NYSE:CNC)

Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with's FREE daily email newsletter.